Potential Therapeutic Application of Mesenchymal Stem Cell-derived Exosomes in SARS-CoV-2 Pneumonia

Overview

Journal Stem Cell Res Ther

Publisher Biomed Central

Date 2020 Aug 16

PMID 32795359

Citations 56

Authors

Ali Akbari

Jafar Rezaie

Affiliations

Soon will be listed here.

Abstract

Background: The outbreak of a new virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now become the main health concern all over the world. Since effective antiviral treatments have not been developed until now, SARS-CoV-2 is severely affecting countries and territories around the world.

Methods: At the present review, articles in PubMed were searched with the following terms: mesenchymal stem cells, exosomes, coronavirus, and SARS-CoV-2, either alone or in a combination form. The most relevant selected functions were mesenchymal stem cell-derived exosomes and SARS-CoV-2 virus infection.

Results: SARS-CoV-2 could damage pulmonary cells and induce secretion of different types of inflammatory cytokines. In the following, these cytokines trigger inflammation that damages the lungs and results in lethal acute respiratory distress syndrome (ARDS). The main characteristic of ARDS is the onset of inflammation in pulmonary, hyaline formation, pulmonary fibrosis, and edema. Mesenchymal stem cell-derived exosomes (MSC-Exo) are believed to have anti-inflammatory effects and immune-modulating capacity as well as the ability to induce tissue regeneration, suggesting a significant therapeutic opportunity that could be used to SARS-CoV-2 pneumonia treatment. Besides, exosomes may serve as a biomarker, drug delivery system, and vaccine for the management of the patient with SARS-CoV-2.

Conclusion: MSC-Exo may serve as a promising tool in the treatment of SARS-CoV-2 pneumonia. However, further work needs to be carried out to confirm the efficacy of exosomes in the treatment of SARS-CoV-2 pneumonia.

Citing Articles

The role of natural exosomes from SHED-MSC in immunoregulation of M0/M1 polarized macrophage cells.

Fallah A, Hosseinzadeh Colagar A, Khosravi A, Mohammad-Hasani A, Saeidi M Front Immunol. 2025; 16:1550280.

PMID: 39991155 PMC: 11842380. DOI: 10.3389/fimmu.2025.1550280.

Current Strategies and Therapeutic Applications of Mesenchymal Stem Cell-Based Drug Delivery.

Matsuzaka Y, Yashiro R Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931374 PMC: 11206583. DOI: 10.3390/ph17060707.

Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.

Lu W, Yan L, Tang X, Wang X, Du J, Zou Z J Transl Med. 2024; 22(1):550.

PMID: 38851730 PMC: 11162060. DOI: 10.1186/s12967-024-05358-6.

The Role of Extracellular Vesicles in Metabolic Diseases.

Gonzalez-Blanco C, Iglesias-Fortes S, Lockwood A, Figaredo C, Vitulli D, Guillen C Biomedicines. 2024; 12(5).

PMID: 38790954 PMC: 11117504. DOI: 10.3390/biomedicines12050992.

Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic.

Yuan D, Bao Y, El-Hashash A Am J Stem Cells. 2024; 13(2):37-58.

PMID: 38765802 PMC: 11101986. DOI: 10.62347/JAWM2040.

References

Pan Y, Zhang D, Yang P, Poon L, Wang Q . Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 2020; 20(4):411-412. PMC: 7128099. DOI: 10.1016/S1473-3099(20)30113-4. View

Bunggulawa E, Wang W, Yin T, Wang N, Durkan C, Wang Y . Recent advancements in the use of exosomes as drug delivery systems. J Nanobiotechnology. 2018; 16(1):81. PMC: 6190562. DOI: 10.1186/s12951-018-0403-9. View

Satija N, Singh V, Verma Y, Gupta P, Sharma S, Afrin F . Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J Cell Mol Med. 2009; 13(11-12):4385-402. PMC: 4515054. DOI: 10.1111/j.1582-4934.2009.00857.x. View

Harrell C, Sadikot R, Pascual J, Fellabaum C, Gazdic Jankovic M, Jovicic N . Mesenchymal Stem Cell-Based Therapy of Inflammatory Lung Diseases: Current Understanding and Future Perspectives. Stem Cells Int. 2019; 2019:4236973. PMC: 6525794. DOI: 10.1155/2019/4236973. View

Hao Q, Gudapati V, Monsel A, Park J, Hu S, Kato H . Mesenchymal Stem Cell-Derived Extracellular Vesicles Decrease Lung Injury in Mice. J Immunol. 2019; 203(7):1961-1972. PMC: 6760999. DOI: 10.4049/jimmunol.1801534. View

Martin-Rufino J, Espinosa-Lara N, Osugui L, Sanchez-Guijo F . Targeting the Immune System With Mesenchymal Stromal Cell-Derived Extracellular Vesicles: What Is the Cargo's Mechanism of Action?. Front Bioeng Biotechnol. 2019; 7:308. PMC: 6856662. DOI: 10.3389/fbioe.2019.00308. View

Chan J, Yuan S, Kok K, To K, Chu H, Yang J . A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395(10223):514-523. PMC: 7159286. DOI: 10.1016/S0140-6736(20)30154-9. View

Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D . COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2020; 201(10):1299-1300. PMC: 7233352. DOI: 10.1164/rccm.202003-0817LE. View

Kuiken T, Fouchier R, Schutten M, Rimmelzwaan G, van Amerongen G, van Riel D . Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003; 362(9380):263-70. PMC: 7112434. DOI: 10.1016/S0140-6736(03)13967-0. View

10.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

11.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

12.

Khatri M, Richardson L, Meulia T . Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. Stem Cell Res Ther. 2018; 9(1):17. PMC: 5789598. DOI: 10.1186/s13287-018-0774-8. View

13.

de Groot R, Baker S, Baric R, Brown C, Drosten C, Enjuanes L . Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013; 87(14):7790-2. PMC: 3700179. DOI: 10.1128/JVI.01244-13. View

14.

Alanagreh L, Alzoughool F, Atoum M . The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms. Pathogens. 2020; 9(5). PMC: 7280997. DOI: 10.3390/pathogens9050331. View

15.

Gunasekaran M, Xu Z, Nayak D, Sharma M, Hachem R, Walia R . Donor-Derived Exosomes With Lung Self-Antigens in Human Lung Allograft Rejection. Am J Transplant. 2016; 17(2):474-484. PMC: 5340154. DOI: 10.1111/ajt.13915. View

16.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

17.

Zhang B, Zhou X, Qiu Y, Song Y, Feng F, Feng J . Clinical characteristics of 82 cases of death from COVID-19. PLoS One. 2020; 15(7):e0235458. PMC: 7347130. DOI: 10.1371/journal.pone.0235458. View

18.

Rezaie J, Rahbarghazi R, Pezeshki M, Mazhar M, Yekani F, Khaksar M . Cardioprotective role of extracellular vesicles: A highlight on exosome beneficial effects in cardiovascular diseases. J Cell Physiol. 2019; 234(12):21732-21745. DOI: 10.1002/jcp.28894. View

19.

Malhotra H, Sheokand N, Kumar S, Chauhan A, Kumar M, Jakhar P . Exosomes: Tunable Nano Vehicles for Macromolecular Delivery of Transferrin and Lactoferrin to Specific Intracellular Compartment. J Biomed Nanotechnol. 2016; 12(5):1101-14. DOI: 10.1166/jbn.2016.2229. View

20.

Fink S, Cookson B . Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005; 73(4):1907-16. PMC: 1087413. DOI: 10.1128/IAI.73.4.1907-1916.2005. View